O ROURKE & COMPANY Inc Sells 611 Shares of Pfizer Inc. $PFE

O ROURKE & COMPANY Inc decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,158 shares of the biopharmaceutical company’s stock after selling 611 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in Pfizer were worth $416,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wetzel Investment Advisors Inc. lifted its stake in Pfizer by 126.4% in the second quarter. Wetzel Investment Advisors Inc. now owns 18,757 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 10,472 shares in the last quarter. Westhampton Capital LLC lifted its stake in Pfizer by 9.9% in the second quarter. Westhampton Capital LLC now owns 46,778 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 4,200 shares in the last quarter. MBA Advisors LLC lifted its stake in Pfizer by 5.1% in the second quarter. MBA Advisors LLC now owns 19,037 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 932 shares in the last quarter. Chicago Capital LLC lifted its stake in Pfizer by 11.0% in the second quarter. Chicago Capital LLC now owns 108,076 shares of the biopharmaceutical company’s stock valued at $2,620,000 after buying an additional 10,701 shares in the last quarter. Finally, One Wealth Advisors LLC bought a new position in Pfizer in the second quarter valued at approximately $320,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on PFE shares. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Price Performance

Shares of PFE opened at $25.46 on Wednesday. The company has a market cap of $144.75 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company’s fifty day simple moving average is $24.55 and its 200 day simple moving average is $24.11. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.